Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Trial to Evaluate the Efficacy & Tolerability of Aprepitant and Palonosetron for the Prevention of CINV in Colorectal Cancer (CRC) Patients Receiving FOLFOX

NCT00381862 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT00381862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00381862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Trial to Evaluate the Efficacy & Tolerability of Aprepitant and Palonosetron for the Prevention of CINV in Colorectal Cancer (CRC) Patients Receiving FOLFOX
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2006
Completion date
July 31, 2008
Enrollment
54 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, nausea and vomiting